MX2020010547A - Anticuerpo agonista del receptor de leptina para usarse en el tratamiento de una disfuncion metabolica o hipoleptinemia. - Google Patents

Anticuerpo agonista del receptor de leptina para usarse en el tratamiento de una disfuncion metabolica o hipoleptinemia.

Info

Publication number
MX2020010547A
MX2020010547A MX2020010547A MX2020010547A MX2020010547A MX 2020010547 A MX2020010547 A MX 2020010547A MX 2020010547 A MX2020010547 A MX 2020010547A MX 2020010547 A MX2020010547 A MX 2020010547A MX 2020010547 A MX2020010547 A MX 2020010547A
Authority
MX
Mexico
Prior art keywords
leptin receptor
hypoleptinemia
treating
metabolic dysfunction
receptor agonist
Prior art date
Application number
MX2020010547A
Other languages
English (en)
Inventor
Panayiotis Stevis
Andrew J Murphy
Jesper Gromada
Judith ALTAREJOS
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020010547A publication Critical patent/MX2020010547A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripción se proporcionan métodos terapéuticos de tratamiento que usan anticuerpos agonistas del receptor de leptina (LEPR), fragmentos de unión a antígeno de estos o composiciones que comprenden los anticuerpos de LEPR o los fragmentos de unión a antígeno de estos. Tales métodos terapéuticos incluyen el tratamiento de padecimientos relacionados con la disfunción metabólica, que incluyen, por ejemplo, lipodistrofia, adiposidad u obesidad, reducción del peso corporal, enfermedad del hígado graso no alcohólico, hiperfagia, hiperglicemia, resistencia a la insulina, dislipidemia, esteatosis hepática e infertilidad.
MX2020010547A 2018-04-06 2019-04-05 Anticuerpo agonista del receptor de leptina para usarse en el tratamiento de una disfuncion metabolica o hipoleptinemia. MX2020010547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862653731P 2018-04-06 2018-04-06
PCT/US2019/026173 WO2019195796A1 (en) 2018-04-06 2019-04-05 A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia

Publications (1)

Publication Number Publication Date
MX2020010547A true MX2020010547A (es) 2020-11-06

Family

ID=66223877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010547A MX2020010547A (es) 2018-04-06 2019-04-05 Anticuerpo agonista del receptor de leptina para usarse en el tratamiento de una disfuncion metabolica o hipoleptinemia.

Country Status (10)

Country Link
US (2) US11608381B2 (es)
EP (1) EP3773713A1 (es)
JP (2) JP7420730B2 (es)
KR (1) KR20200141461A (es)
CN (1) CN112040980A (es)
AU (1) AU2019249273A1 (es)
CA (1) CA3094400A1 (es)
IL (1) IL277634A (es)
MX (1) MX2020010547A (es)
WO (1) WO2019195796A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7328982B2 (ja) * 2018-10-11 2023-08-17 住友化学株式会社 プロピレンオキサイド精製装置、及び、プロピレンオキサイドの製造方法
US11138441B2 (en) * 2019-12-06 2021-10-05 Baidu Usa Llc Video action segmentation by mixed temporal domain adaption
BR112023004716A2 (pt) * 2020-09-15 2023-05-09 Regeneron Pharma Uso de agonistas de lepr para dor
WO2022178382A1 (en) * 2021-02-22 2022-08-25 Regeneron Pharmaceuticals, Inc. Method for diagnosing and treating partial lipodystrophy
CN114456124B (zh) * 2021-12-30 2023-04-21 华南农业大学 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US6977240B1 (en) 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
CA2241564C (en) 1996-01-08 2013-09-03 Genentech, Inc. Wsx receptor and ligands
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
US7063958B1 (en) 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
WO1997027286A1 (en) 1996-01-23 1997-07-31 Progenitor, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
US5965521A (en) 1997-02-25 1999-10-12 Eli Lilly Company Pulsatile delivery of leptin receptor ligands
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
KR100459493B1 (ko) * 2002-01-31 2004-12-03 김기수 골다공증의 발생 위험을 예측하는 방법 및 이를 이용한골다공증의 유전적 위험 인자에 대한 진단 키트
FR2852397B1 (fr) 2003-03-10 2005-04-29 Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal.
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
EP1874816A4 (en) 2005-04-26 2010-08-25 Medimmune Inc MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
AU2009313560B2 (en) 2008-11-07 2016-04-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
BR112013012213A2 (pt) * 2010-11-17 2020-09-01 Chugai Seiyaku Kabushiki Kaisha moléculas de ligação a antígeno mul tlespecíficas tendo função alternativa à função dos fatores viii, ix e x de coagulação sanguínea, e anticorpo bies- 5 pecífico, seus usos na prevenção ou tratamento de hemorragia, ácido nucleico, vetor, célula, método para produzir as referidas moléculas de ligação, composição farmacêutica e kit
EP2672999A2 (en) 2011-02-10 2013-12-18 Roche Glycart AG Improved immunotherapy
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EA035987B1 (ru) 2012-09-12 2020-09-09 Джензим Корпорейшн ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ АФФИННОСТЬЮ К Fc-ГАММА РЕЦЕПТОРАМ
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
DK3108255T3 (da) 2014-02-18 2020-11-09 Inst Nat Sante Rech Med Fremgangsmåder og farmaceutiske sammensætninger til behandling af sygdomme medieret af nrp-1/obr-komplekssignalvejen
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP3538554A1 (en) 2016-11-08 2019-09-18 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
CN107760761A (zh) 2017-11-10 2018-03-06 江苏省农业科学院 一种加强瘦素激发lepr信号转导的方法
MX2020006508A (es) 2017-12-18 2020-09-17 Regeneron Pharma Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas.

Also Published As

Publication number Publication date
JP7420730B2 (ja) 2024-01-23
EP3773713A1 (en) 2021-02-17
CN112040980A (zh) 2020-12-04
JP2021532057A (ja) 2021-11-25
US20220280641A1 (en) 2022-09-08
RU2020133603A (ru) 2022-05-06
CA3094400A1 (en) 2019-10-10
KR20200141461A (ko) 2020-12-18
US20190309079A1 (en) 2019-10-10
AU2019249273A1 (en) 2020-10-15
JP2024045204A (ja) 2024-04-02
US11608381B2 (en) 2023-03-21
IL277634A (en) 2020-11-30
WO2019195796A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
MX2020010547A (es) Anticuerpo agonista del receptor de leptina para usarse en el tratamiento de una disfuncion metabolica o hipoleptinemia.
MX2019012364A (es) Proteinas de union a antigenos trem2 y usos de estas.
PH12020551025A1 (en) Incretin analogs and uses thereof
PH12020551024A1 (en) Incretin analogs and uses thereof
MX2019013132A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
WO2016081746A8 (en) Antibodies comprising modified heavy constant regions
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
EP4317185A3 (en) Fully-human post-translationally modified antibody therapeutics
UA92504C2 (en) Anti-myostatin monoclonal antibody
MX349054B (es) Leptinas altamente solubles.
MX2010002053A (es) Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento.
MX2017005280A (es) Coagonistas de los receptores de glucagon y de glp-1.
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
PH12021550764A1 (en) Trem2 stabilizing antibodies
MX2017012864A (es) Analogo acilado del glucagon.
TN2014000513A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2006049933A3 (en) Compositions and methods for the treatment of obesity and sexual dysfunction
MX2020012081A (es) Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.
MX2021003146A (es) Anticuerpos anti-ifnar1 para tratar enfermedades autoinmunitarias.
TN2018000021A1 (en) ANTl-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY.
PH12021551153A1 (en) Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
EP4279086A3 (en) Compositions and methods for treating cancer with anti-cd19 immunotherapy
BR112018001707A2 (pt) agonistas de receptor 5-ht2c e composições e métodos de uso
JOP20200069A1 (ar) أجسام مضادة لـ pacap
MX2017013177A (es) Anticuerpo anti-vegfr2 humano para terapia del cancer anti-angiogenica y dirigida.